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Abstract
Background
Community-acquired pneumonia (CAP) is an important cause of illness and death world-
wide, particularly among the elderly. Previous studies on the factors associated with mortal-
ity in patients hospitalized for CAP revealed a direct association between the type of
microorganism involved, the characteristics of the patient and mortality. Vaccination status
against pneumococcal disease was not considered. We conducted a retrospective analysis
on the mortality rates after a first hospitalization for CAP in north-east Italy with a view to
examining especially the role of anti-pneumococcal vaccination as a factor associated with
pneumonia-related mortality at one year.
Method
Between 2012–2013, patients aged 65+ hospitalized with a primary diagnosis of CAP, iden-
tified based on International Classification of Diseases, Ninth Revision, Clinical Modification
codes 481–486, were enrolled in the study only once. Patients were divided into three
groups by pneumococcal vaccination status: 1) 13-valent pneumococcal conjugate vaccine
(PCV13) prior to their hospitalization; 2) 23-valent pneumococcal polysaccharide vaccine
(PPV23) within 5 years before hospitalization and 3) unvaccinated or PPV23 more than 5
years prior to admission. Gender, age, length of hospital stay and influenza vaccination
were considered. Comorbidities were ascertained by means of a properly coded diagnosis.
Every patient was followed up for 1 year and the outcome investigated was mortality for any
cause and for pneumonia.
Results
A total of 4,030 patient were included in the study; mean age at the time of admission to hos-
pital was 84.3±7.7; 50.9% were female. 74.2% of subjects had at least one comorbidity;
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73.7% has been vaccinated against influenza. Regard to pneumococcal vaccine, 80.4% of
patients were not vaccinated, 14.5% vaccinated with PPV23 and 5.1% with PCV13. The 1-
year survival rates after hospitalization for pneumonia were 83.6%, 85.9% and 89.3% in the
unvaccinated, PPV23 and PCV13 groups, respectively. Regression analysis indicated that
the risk of death due to pneumonia increased significantly with age (adjusted OR: 1.073;
1.061–1.085), shorter hospital stay (adjusted OR: 0.981; 0.971–0.990), and male gender
(adjusted OR: 1.372; 1.165–1.616). The model also confirmed the pneumococcal 13-valent
conjugated vaccine as an independent protective factor for mortality-related pneumonia
(adjusted OR: 0.599; 0.390–0.921).
Conclusion
The main finding of our observational cohort study is a high mortality rate among elderly
patients admitted to hospital for pneumonia. The present study suggests a protective role
for PCV13 vaccination.
Introduction
Community-acquired pneumonia (CAP) is an important cause of illness and death worldwide,
particularly among the elderly [1]. Streptococcus pneumoniae (SP) is the most common bacte-
rial cause of CAP among adults in industrialized countries, and pneumococcal infections are
considered a major global public health issue for all age groups. The pathogens reportedly
identified as being responsible for pneumonia may vary, however, depending on the equip-
ment and/or expertise available at in-hospital laboratories, the study designs used in published
reports, the seasons of the year, and the regions where studies are conducted [2].
The epidemiological picture of CAP-related hospitalization trends varies, with some coun-
tries recording a drop in the rates due to herd effects among elderly, while others report rising
numbers of hospital admissions for CAP, possibly as a result of the rising proportions of
elderly people in the general populations, and their higher prevalence of concomitant clinical
conditions (such as chronic obstructive pulmonary disease or diabetes) [3–7]. Whatever a
region’s CAP-related hospitalization rate, about 70% of cases involve patients aged 65 years
and older [8, 9].
CAP is associated with mortality rates that reflect the site of patient care: while outpatients
have a<5% risk of dying, hospitalized cases have a mortality rate of 12%, and the chances of
death for patients admitted to the intensive care unit exceeds 30% [10]. It is very important to
assess the severity of pneumonia cases accurately to ensure their appropriate management,
given its impact on the related mortality risk and on the cost of care for these patients.
Previous studies on the factors associated with mortality in patients hospitalized for CAP
revealed a direct association between the type of microorganism involved, the characteristics
of the patient (age, sex and comorbidities) and mortality [8]. Vaccination status against pneu-
mococcal disease was not considered, however, due to a shortage of data because PCV13 vacci-
nation in the elderly was introduced only recently.
We conducted a retrospective analysis of the mortality rates after a first hospitalization for
CAP in north-east Italy with a view to examining especially the role of anti-pneumococcal vac-
cination as a factor associated with pneumonia-related mortality at one year.
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Material and Methods
From 1 January 2012 to 31 December 2013, a retrospective observational cohort study was
conducted on data routinely collected by the health services in Friuli Venezia Giulia (FVG), a
region of north-eastern Italy. At the time of the study, FVG had a population of about 1.2 mil-
lion with an average age of 46.2 years, an old-age index of 191.8%, and a mortality rate of 11.2
per 1,000 population. The region had 4,226 hospital beds, about 3.5 per 1,000 population. The
overall hospitalization rate was 106.1 per 1,000 population, for a hospital bed occupation rate
of 76.5% and a mean hospital stay of 7.2 days.
Setting
The FVG Regional Authority operates an automated, centralized system for recording and
pooling data on health care funded by the Italian National Health Service, and patients are
identified in the database by means of unique anonymous personal codes. The following health
data were used for this study: hospital discharge records (HDRs, coded according to the Inter-
national Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM]) of all
public and accredited private hospitals; mortality records (MR, coded according to the ICD-
9-CM); health-related tax exemptions (HTEs; coded using an Italian national coding system);
drug prescriptions (DPs; based on the Anatomical Therapeutic Chemical classification system
[ATC]); and the FVG regional cancer and vaccination registries (VR).
An active program of immunization for the elderly with 13-valent pneumococcal conjugate
vaccine (PCV13) was first introduced in FVG in 2012, when PCV13 was adopted instead of
the 23-valent pneumococcal polysaccharide vaccine (PPV23). Pneumococcal vaccination was
offered in co-administration with influenza vaccine.
Patients
Patients aged 65 years older who were hospitalized with a primary diagnosis of pneumonia,
based on ICD-9-CM codes 481–486 (CAP-related hospitalizations) were enrolled in the study
only once, on their first hospitalization (i.e. they had not been admitted to hospital for pneu-
monia during the previous year).
Pneumonia was diagnosed on the grounds of instrumental, clinical and microbiological
findings, and a specific ICD code was assigned as follows: 481 for Streptococcus pneumoniae,
482 for other bacterial pneumonia (Klebsiella pneumoniae, Pseudomonas, Haemophilus influ-
enza, Streptococcus spp, Staphylococcus and other specified bacteria), 483 for pneumonia due to
other specified organism (Mycoplasma pneumoniae and Chlamydia), 484 for pneumonia in
infectious diseases classified elsewhere, and 485–486 for pneumonia without a causative organ-
ism identified.
Patients were divided into three groups by pneumococcal vaccination status. Group 1
included patients vaccinated with PCV13 prior to their hospitalization; Group 2 concerned
those vaccinated with PPV23 within 5 years before hospitalization (based on data on the dura-
tion of vaccine-induced protection [11]); and Group 3 included patients who had never been
vaccinated, and those vaccinated with PPV23 more than 5 years prior to admission. Influenza
vaccination was considered if it had been performed no more than one year before the
patient’s hospitalization.
Comorbidity
For all subjects, comorbidities were identified by means of their HDRs, HTEs, and DPs
recorded between 2000 and 2011. Patients with asthma were identified from HDRs containing
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a diagnosis (primary or secondary) of asthma (ICD-9-CM code: 493), or from prescriptions
for anti-asthma drugs (ATC code: R03A, R03CC02, R03CC04, R03CK, R03DC01, R03DC03),
or HTEs for asthma (code: 007.493). Cases of chronic obstructive pulmonary disease (COPD)
were identified from HDRs with ICD-9-CM codes 490, 491, 492, 494 and 496. Cases of
diabetes mellitus were identified from HDRs with ICD-9-CM codes 250 or at least two DPs
for antidiabetic drugs (ATC code: A10A and A10B) at two different times, or HTEs (code:
013.250). Cases of cancer were identified from the FVG cancer registry.
Outcome
Deaths during the follow-up were ascertained from the records in the FVG Cause of Death
Register. The cause of death of residents of the region is reported on death certificates by the
medical examiners, then ICD coded and validated by personnel at the local health agencies.
The coverage of this register is 100%. Mortality was recorded during a 1-year follow-up after a
pneumonia-related hospital stay, and was classified as: in-hospital; at 30 days after discharge;
and at 1 year after discharge. All deaths were included in one of five groups based on the main
cause of death depending on the organ system involved, as described by Bruns et al. [12]: (i)
pneumonia (ICD: 481–486); (ii) COPD and allied conditions (ICD: 490–496); (iii) vascular
disease (ICD: 390–459); (iv) malignancy (ICD: 140–239); and (v) others (all other ICD).
Statistical analysis
A descriptive analysis was conducted on patients’ demographics and clinical data. Data were
presented as percentages for categorical variables and compared using the chi-square test or
Fisher’s exact test, or as means ± standard deviations (SD) for continuous variables, which
were compared using Student’s t-test for unpaired data, performing a priori tests for equality
of variances. The mortality rate was calculated by group, with the corresponding 95% CIs.
Patient survival after hospital discharge was assessed with a Kaplan-Meier survival analysis.
Survival curves were compared using log-rank and Wilcoxon’s test. Mortality risk factors were
analyzed with Cox’s regression model.
The mortality observed in our cohort was compared with the expected total mortality in the
Friuli Venezia Giulia region’s population aged 65 years over hospitalized during the study
period for any reason (with no other hospital admissions in the previous year), stratified by
age and gender. This enabled us to estimate standardized mortality ratios (SMRs) with 95%
Confidence Interval (95% CI).
A P-value of<0.05 was accepted as statistically significant. The analyses were performed
using the Statistical Package for the Social Sciences (SPSS 22.0; SPSS Inc., Chicago, IL, USA).
Ethics statement
Data were treated with full confidentiality in accordance with Italian legislation. Before the
database was made available to the authors, patient identifiers were replaced with anonymous
codes that make it impossible to identify the individuals concerned. It was unnecessary to
obtain patients’ informed consent, given the anonymous nature of the data and its mandatory
recording (anonymized data may be analyzed and used in aggregate form for scientific studies
without further authorization) [13]. This study complies with the Declaration of Helsinki and
the study protocol was approval by the ethical committee of the Padua Provincial Authority.
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Results
During the study period, 79,294 all-cause hospitalizations were extrapolated from the regional
HDRs. Among all these hospital admissions, 4,766 (6.0%) were CAP-related, but 736 of these
cases were excluded from the study due to patients having being vaccinated with a pneumo-
coccal vaccine after their discharge from hospital. Among the remaining 4,030 patients
included in our study, a specific pneumonia diagnosis was mentioned for 6.6% of admissions
(Streptococcus pneumoniae in 2.7%, other bacterial pneumonia in 3.9%), while the etiology was
not specified for 93.4%. There was a slight majority of females (50.9%). The mean age of the
sample at the time of admission to hospital was 84.3±7.7, and 70.2% of the patients were at
least 80 years old. In the cohort as a whole, 73.7% had been vaccinated against influenza; 74.2%
patients had at least one comorbidity, and males were significantly more affected by all the
comorbidities analyzed (p<0.05). The mean hospital stay was 12.7±11.1 days.
The flow-chart in Fig 1 summarizes the patient and study group selection process.
During the one-year follow-up, the deaths observed among patients aged 65 or older who
were hospitalized for CAP amounted to 2,291, as opposed to an expected 1,057.3 deaths based
on the regional rate, which results in a SMR for our cohort of 2.17 (95% CI: 2.08–2.26). The
SMR was 2.20 (95% CI: 2.07–2.32) for males, and 2.07 (95% CI: 1.95–2.19) for females. The
SMRs by time of death are shown in Table 1.
Table 2 shows the distribution of the main causes of death by time of death. Within 30 days
after discharge, respiratory disease was the leading cause of death, with 540 patients dying of
Fig 1. Patient selection.
doi:10.1371/journal.pone.0166637.g001
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pneumonia, and 48 due to COPD (40.9% pneumonia alone and 44.5% pneumonia plus
COPD, respectively). At 1 year after discharge, on the other hand, vascular diseases had
become the leading cause of death (36.0%). Of the 639 of all deaths within 1 year due to vascu-
lar diseases, 48.6% were due to heart disease, 30.8% to cerebrovascular disease, 13.1% to hyper-
tensive disease, and 7.4% to other diseases of the circulatory system.
As concerns pneumococcal vaccination status, 80.4% of patients were not vaccinated,
14.5% were vaccinated with PPV23, and 5.1% with PCV13 (Fig 1). The subjects administered
PPV23 vaccine were of significantly younger age than the other two groups (83.3±8.1 years old
in the PPV23 group versus 84.7±7.4 in the PCV13 group, and 84.4±7.7 for the unvaccinated
subjects; p<0.05). The frequency of comorbidities was significantly higher among subjects vac-
cinated with PCV13 (p<0.05). The rate of vaccination against influenza virus was significantly
higher among subjects also vaccinated against pneumococcal disease (p<0.05). The cumula-
tive all-cause mortality rate was lower among patients vaccinated with PCV13 (102 deaths,
49.5%), than among the unvaccinated patients (1,857 deaths, 57.3%; p<0.05) or the group vac-
cinated with PPV23 (332 deaths, 56.9%; p<0.05). Table 3 shows the demographics and clinical
features of patients grouped by pneumococcal vaccination status.
Fig 2 shows the distribution of the causes of death by pneumococcal vaccination status.
Among the deaths due specifically to pneumonia, a mortality rate of 10.7% (95% CI: 6.5%-
14.9%) was calculated in the PCV13 group, which was lower than in the unvaccinated or
PPV23 groups, with 16.4% (95% CI: 15.1%-17.7%) and 14.1% (95% CI: 11.2%-16.9%),
respectively.
Specifically as concerns pneumonia, the survival rates at 1-year after hospitalization were
83.6%, 85.9% and 89.3% in the unvaccinated, PPV23 and PCV13 groups, respectively. The
mean survival for this cause of death was 10.2±0.1 months in the unvaccinated group, 10.5±0.2
months in the PPV23 group, and 10.9± 0.2 months in the PCV13 group (Fig 3).
Regression analysis indicated that the risk of death due to pneumonia increased signifi-
cantly with age (adjusted OR: 1.073; 95% CI: 1.061–1.085), shorter hospital stays (adjusted OR:
0.981; 95% CI: 0.971–0.990), and male gender (adjusted OR: 1.372; 95% CI: 1.165–1.616). The
Table 1. Standardized mortality rates (SMR) by gender and time of death.
Time of death Male Female Total
SMR 95% CI SMR 95% CI SMR 95% CI
In-hospital mortality 3.01 5.22–6.24 2.66 2.42–2.89 2.86 2.68–3.04
30-day mortality 2.24 1.92–2.59 2.19 1.89–2.54 2.25 2.02–2.49
1-year mortality 1.73 1.58–1.88 1.65 1.51–1.81 1.73 1.62–1.83
Cumulative mortality 2.20 2.07–2.32 2.07 1.95–2.19 2.17 2.08–2.26
doi:10.1371/journal.pone.0166637.t001
Table 2. Distribution of 2,291 patients who died by time and cause of death.
Cause of death In-hospital At 30 days after
discharge
At 1 year after discharge Cumulative mortality
n (%) n (%) n (%) n %
Pneumonia 480 (49.4) 60 (17.2) 95 (9.8) 635 (27.7)
COPD and allied conditions 37 (3.8) 11 (3.2) 42 (4.3) 90 (3.9)
Vascular disease 171 (17.6) 118 (33.9) 350 (36.0) 639 (27.9)
Malignancy 47 (4.8) 56 (16.1) 176 (18.1) 279 (12.2)
Other 237 (24.4) 103 (29.6) 308 (31.7) 648 (28.3)
All causes 972 348 971 2,291
doi:10.1371/journal.pone.0166637.t002
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Table 3. Characteristics of the study population by pneumococcal vaccination status.
Variables Pneumococcal vaccination status
Not vaccinated PPV23 PCV13
n (%) n (%) n (%)
Gender [n(%)]
Males 1,577 (48.7) 293 (50.3) 107 (51.9)
Females 1,664 (51.3) 290 (49.7) 99 (48.1)
Age groups [n(%)]
65–69 112 (3.5) 29 (5.0) 3 (1.5)
70–74 339 (10.5) 87 (14.9) 21 (10.2)
75–79 479 (14.8) 96 (16.5) 34 (16.5)
80–84 643 (19.8) 91 (15.6) 41 (19.9)
85+ 1,668 (51.5) 280 (48.0) 107 (51.9)
At least one comorbidity [n(%)] 2,380 (73.4) 440 (75.5) 169 (82.0)
Asthma 1,253 (38.7) 235 (40.3) 94 (45.6)
COPD 583 (18.0) 116 (19.9) 48 (23.3)
Chronic heart diseases 1,237 (38.2) 233 (40.0) 78 (37.9)
Diabetes 792 (24.4) 162 (27.8) 56 (27.2)
Malignant neoplasms 518 (16.0) 99 (17.0) 30 (14.6)
Influenza vaccination [n(%)] 2,251 (69.5) 526 (90.2) 204 (99.0)
All-cause mortality
in-hospital 803 (24.8) 133 (22.8) 36 (17.5)
at 30 days 282 (8.7) 52 (8.9) 14 (6.8)
at 1 year 772 (23.8) 147 (25.2) 52 (25.2)
cumulative 1,857 (57.3) 332 (56.9) 102 (49.5)
doi:10.1371/journal.pone.0166637.t003
Fig 2. Mortality rate (%) by cause of death and pneumococcal vaccination status.
doi:10.1371/journal.pone.0166637.g002
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model also confirmed the pneumococcal 13-valent conjugated vaccine as an independent pro-
tective factor against pneumonia mortality (adjusted OR: 0.599; 95% CI: 0.390–0.921).
Discussion
The main finding of our observational cohort study is that hospital admission for CAP in the
elderly was associated with a higher mortality rate than hospitalization for other illnesses. We
found the pneumonia-related mortality 2.17-fold higher than was to be expected judging from
the overall hospitalization data, adjusted for age and gender. The difference was greater for in-
hospital and 30-day mortality, then dropped to a 1.73-fold increase in one-year mortality. The
consistently high all-cause mortality rate for patients with CAP observed in our population
reflects the findings of other studies, and may represent an accurate estimate of the mortality
risk associated with an episode of CAP among people over 65 [14].
Several studies have reported one-year mortality rates for subjects hospitalized for CAP in
the range of 7% to 41%, depending on the population considered [2, 15–21]. Our population
was very elderly and 75% of these patients had chronic conditions such as asthma and chronic
heart disease. Our 30-day mortality rate could be due to the fact that only the more severe
cases of pneumonia are hospitalized, whereas most patients developing pneumonia in our
Fig 3. One-year survival after pneumonia by patients’ vaccination status.
doi:10.1371/journal.pone.0166637.g003
Pneumococcal Conjugated Vaccine and Community-Acquired Pneumonia in the Elderly
PLOS ONE | DOI:10.1371/journal.pone.0166637 November 15, 2016 8 / 11
geographical area are not admitted to hospital. In fact, our region has lower hospitalization
rates for pneumonia than other Italian regions, but a higher case fatality rate [22].
The cause of death differed, depending on the time of its occurrence. Pneumonia was the
main cause of early death, confirming that hospital admission was reserved for the most severe
cases. Later causes of death were attributed mainly to chronic conditions such as vascular dis-
ease, and malignancies, not to recurrent pneumonia, a finding consistent with previous studies
[13–14, 23–24]. As in other reports, our findings further support the impression that cardio-
vascular events may play an important part in the long-term outcome of hospital survivors of
CAP [25–27].
Our sample revealed a better one-year survival rate among subjects who had been immu-
nized with conjugate vaccine against pneumococcal disease prior to their admission to hospi-
tal. Their lower mortality over the study period is attributable mainly to a lower death rate
related to lung disease, especially when pneumonia was considered alone. The one-year sur-
vival rate after hospitalization for pneumonia was significantly higher (about 7%) for the
PCV13-immunized patients than for the other two groups. Our analysis revealed a protective
role of pneumococcal vaccination to survival of subjects. As for the other factors investigated,
advanced age, male sex, and a shorter hospital stay were also associated with a lower one-year
survival rate after hospitalization for pneumonia.
There is currently a shortage of information on the role of PCV13 vaccination for adults in
protecting against mortality due to pneumococcal disease [28]. Trials conducted on pneumo-
coccal polysaccharide vaccines have failed to provide evidence to support the routine use of
PPVs to prevent all-cause pneumonia or the related mortality, though some studies indicate
that PPVs confer protection against invasive pneumococcal disease (IPD) [29–30]. The present
study is one of the few in which outcome was assessed in an open population in relation to
patients’ vaccination status. Our findings warrant further investigation in studies with a longer
follow-up and larger samples of subjects.
The results of the CAPITA study indicated that vaccination is effective in reducing CAP
and IPD in individuals over 65 years old with no chronic comorbidities [31]. Our findings sug-
gest instead that vaccination is effective in preventing fatalities among patients hospitalized for
an episode of severe CAP. The two studies were conducted in very different settings, since our
sample was generally frail, and our follow-up began with the episode of CAP and should be
further investigated to see how elderly patients with chronic diseases may benefit in survival
terms.
Our study has some limitations, the first of which concerns the small number of patients in
the PCV13-vaccinated group: this could be partly explained by the protective effect of immuni-
zation against CAP and IPD (as seen in the CAPITA trial), which would consequently reduce
the likelihood of hospitalization for PCV13-vaccinated patients with CAP because their disease
would be less severe and they would be managed as outpatients. Further studies could there-
fore focus on the role of vaccination in reducing CAP-related hospitalizations. A second possi-
ble limitation lies in that HDRs provide no microbiological data, though, according to the
literature, an estimated 27.3% of cases of CAP are attributable to Streptococcus pneumoniae
[32], and consequently potentially preventable by means of vaccination.
The strengths of our work lie in having designed our retrospective cohort study to investi-
gate whether pneumonia is an event that increases short- or long-term mortality in a well-
defined patient population by means of data routinely collected by the public health service,
and following patients up for up to 1 year after their discharge from hospital. The analysis of
routinely-available records can prove an efficient method for monitoring trends in the state of
health of particular populations.
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Conclusions
The results of the present study confirm a higher mortality rate among elderly people hospital-
ized for pneumonia and suggest a protective role for PCV13 vaccination. Long-term studies
are needed, however, to confirm the benefit of PCV13 in reducing pneumonia-related mortal-
ity in the elderly. Meanwhile, efforts should be made to improve vaccination programs for the
elderly, given the higher frequency of chronic diseases in this population.
Author Contributions
Conceptualization: VB SC TG.
Data curation: PF.
Formal analysis: VB SC PF.
Methodology: AB.
Supervision: VB TB.
Validation: PR PF.
Writing – original draft: VB SC CB TB.
Writing – review & editing: VB SC.
References
1. Stupka JE, Mortensen EM, Anzueto A, Restrepo MI. Community-acquired pneumonia in elderly
patients. Aging Health. 2009; 5(6):763–774. doi: 10.2217/ahe.09.74 PMID: 20694055
2. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia
among adults in Europe. Thorax. 2010; 67:71–79. doi: 10.1136/thx.2009.129502 PMID: 20729232
3. Griffin MR, Zhu Y, Moore MR, Whitney CG, Grijalva CG. U.S. Hospitalizations for pneumonia after a
decade of pneumococcal vaccination. N Engl J Med. 2013; 369: 155–163. doi: 10.1056/
NEJMoa1209165 PMID: 23841730
4. Fry AM, Shay DK, Holman RC, Curns AT, Anderson LJ. Trends in hospitalizations for pneumonia
among persons aged 65 years or older in the United States, 1988–2002. JAMA. 2005; 294: 2712–
2719. doi: 10.1001/jama.294.21.2712 PMID: 16333006
5. Hebert PL, McBean AM, Kane RL. Explaining trends in hospitalizations for pneumonia and influenza in
the elderly. Med Care Res Rev. 2005; 62: 560–582. doi: 10.1177/1077558705279310 PMID:
16177458
6. Thomsen RW, Riis A, Norgaard M, Jacobsen J, Christensen S, McDonald CJ, et al. Rising incidence
and persistently high mortality of hospitalized pneumonia: a 10-year population-based study in Den-
mark. J Intern Med. 2006; 259: 410–417. doi: 10.1111/j.1365-2796.2006.01629.x PMID: 16594909
7. Oosterheert JJ, Bonten MJ, Hak E, Lammers JW, Schneider MM, Hoepelman IM. The increase in pneu-
monia-related morbidity and mortality among adults in the Netherlands and possible explanations for it
[in Dutch]. Ned Tijdschr Geneeskd. 2004; 148: 1765–1769. PMID: 15495939
8. Millett ER, De Stavola BL, Quint JK, Smeeth L, Thomas SL. Risk factors for hospital admission in the 28
days following a community-acquired pneumonia diagnosis in older adults, and their contribution to
increasing hospitalisation rates over time: a cohort study. BMJ Open. 2015; 5(12):e008737. doi: 10.
1136/bmjopen-2015-008737 PMID: 26631055
9. Baldo V, Cocchio S, Baldovin T, Buja A, Furlan P, Bertoncello C, et al. A population-based study on the
impact of hospitalization for pneumonia in different age groups. BMC Infect Dis. 2014; 14:485. doi: 10.
1186/1471-2334-14-485 PMID: 25192701
10. Brito V, Niederman MS. Predicting mortality in the elderly with community-acquired pneumonia: should
we design a new car or set a new ‘speed limit’? Thorax. 2010; 65:944–945 doi: 10.1136/thx.2010.
138131 PMID: 20965932
11. WHO Pneumococcal vaccines, WHO position paper– 2012. Wkly Epidemiol Rec. 2012;87:129–144.
Pneumococcal Conjugated Vaccine and Community-Acquired Pneumonia in the Elderly
PLOS ONE | DOI:10.1371/journal.pone.0166637 November 15, 2016 10 / 11
12. Bruns AH, Oosterheert JJ, Cucciolillo MC, El Moussaoui R, Groenwold RH, Prins JM, et al. Cause-spe-
cific long-term mortality rates in patients recovered from community-acquired pneumonia as compared
with the general Dutch population. Clin Microbiol Infect. 2011; 17: 763–768. doi: 10.1111/j.1469-0691.
2010.03296.x PMID: 20807226
13. Garante per la protezione dei dati personali. Autorizzazione generale al trattamento dei dati personali
effettuato per scopi di ricerca scientifica—1˚ marzo 2012. Gazzetta Ufficiale della Repubblica Italiana.
2012; 72: 47–52.
14. Eurich DT, Marrie TJ, Minhas-Sandhu JK, Majumdar SR. Ten-year mortality after community-acquired
pneumonia. A prospective cohort. Am J Respir Crit Care Med. 2015; 192: 597–604. doi: 10.1164/rccm.
201501-0140OC PMID: 26067221
15. Tan YK, Khoo KL, Chin SP, Ong YY. Aetiology and outcome of severe community-acquired pneumonia
in Singapore. Eur Respir J. 1998; 12: 113–115. doi: 10.1183/09031936.98.12010113 PMID: 9701424
16. Kaplan V, Clermont G, Griffin MF, Kasal J, Watson RS, Linde-Zwirble WT, et al. Pneumonia: still the old
man’s friend? Arch Intern Med. 2003; 163: 317–323. doi: 10.1001/archinte.163.3.317 PMID: 12578512
17. Adamuz J, Viasus D, Jimenez-Martinez E, Isla P, Garcia-Vidal C, Dorca J, et al. Incidence, timing and
risk factors associated with 1-year mortality after hospitalization for community-acquired pneumonia. J
Infect. 2014; 68: 534–541. doi: 10.1016/j.jinf.2014.02.006 PMID: 24534605.
18. Yende S, Alvarez K, Loehr L, Folsom AR, Newman AB, Weissfeld LA, et al. Epidemiology and long-
term clinical and biologic risk factors for pneumonia in community-dwelling older Americans: analysis of
three cohorts. Chest. 2013; 144: 1008–1017. doi: 10.1378/chest.12-2818 PMID: 23744106.
19. Khawaja A, Zubairi AB, Durrani FK, Zafar A. Etiology and outcome of severe community acquired pneu-
monia in immunocompetent adults. BMC Infect Dis. 2013; 13:94. doi: 10.1186/1471-2334-13-94 PMID:
23425298
20. Yu H, Rubin J, Dunning S, Li S, Sato R. Clinical and economic burden of community-acquired pneumo-
nia in the Medicare fee-for-service population. J Am Geriatrics Soc. 2012; 60 (11) 2137–2143.
21. Cavallazzi R, Wiemken T, Arnold FW, Luna CM, Bordon J, Kelley R, Feldman C, Chalmers JD, Torres
A, Ramirez J. Outcomes in patients with community-acquired pneumonia admitted to the intensive care
unit. Respir Med. 2015; 109(6):743–750. doi: 10.1016/j.rmed.2015.04.007 PMID: 25956021
22. Baldo V, Cocchio S, Gallo T, Furlan P, Clagnan E, Del Zotto S, et al. Impact of pneumococcal conjugate
vaccination: a retrospective study of hospitalization for pneumonia in North-East Italy. JPMH. 2016; in
press.
23. Hedlund JU, Ortqvist AB, Kalin ME, Granath F. Factors of importance for the long-term prognosis after
hospital-treated pneumonia. Thorax. 1993; 48: 785–789. PMID: 8211867
24. Yende S, D’Angelo G, Kellum JA, Weissfeld L, Fine J, Welch RD, et al. Inflammatory markers at hospital
discharge predict subsequent mortality after pneumonia and sepsis. Am J Respir Crit Care Med. 2008;
177: 1242–1247. doi: 10.1164/rccm.200712-1777OC PMID: 18369199
25. Holter JC, Ueland T, Jenum PA, Mu¨ller F, Brunborg C, Frøland SS, et al. Risk factors for long-term mor-
tality after hospitalization for community-acquired pneumonia: A 5-year prospective follow-up study.
PLoS One. 2016; 11(2):e0148741. doi: 10.1371/journal.pone.0148741 PMID: 26849359
26. Corrales-Medina VF, Alvarez KN, Weissfeld LA, Angus DC, Chirinos JA, Chang CC, et al. Association
between hospitalization for pneumonia and subsequent risk of cardiovascular disease. JAMA. 2015;
313: 264–274. doi: 10.1001/jama.2014.18229 PMID: 25602997
27. Cangemi R, Calvieri C, Falcone M, Bucci T, Bertazzoni G, Scarpellini MG, et al. Relation of cardiac com-
plications in the early phase of community-acquired pneumonia to long-term mortality and cardiovascu-
lar events. Am J Cardiol. 2015; 116: 647–651. doi: 10.1016/j.amjcard.2015.05.028 PMID: 26089009
28. Van Hoek AJ, Miller E. Cost-Effectiveness of Vaccinating Immunocompetent65 Year Olds with the
13-Valent Pneumococcal Conjugate Vaccine in England. PLoS One. 2016; 11(2):e0149540. doi: 10.
1371/journal.pone.0149540 PMID: 26914907
29. Vila-Corcoles A, Ochoa-Gondar O, Guzma´n JA, Rodriguez-Blanco T, Salsench E, Fuentes CM: Effective-
ness of the 23-valent polysaccharide pneumococcal vaccine against invasive pneumococcal disease in
people 60 years or older. BMC Infect Dis. 2010, 10: 73–doi: 10.1186/1471-2334-10-73 PMID: 20298596
30. Moberley S, Holden J, Tatham DP, Andrews RM. Vaccines for preventing pneumococcal infection in
adults. Cochrane Database Syst Rev. 2013; 1. doi: 10.1002/14651858.CD000422.pub2
31. Mangen MJ, Rozenbaum MH, Huijts SM, van Werkhoven CH, Postma DF, Atwood M et al. Cost-effec-
tiveness of adult pneumococcal conjugate vaccination in the Netherlands. Eur Respir J. 2015; 46(5):
1407–1416. doi: 10.1183/13993003.00325-2015 PMID: 26160871
32. Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O’Brien KL, AGEDD Adult Pneumococcal Burden
Study Team. A systematic review and meta-analysis of diagnostic techniques. PLoS One. 2013; 8(4).
doi: 10.1371/journal.pone.0060273 PMID: 23565216
Pneumococcal Conjugated Vaccine and Community-Acquired Pneumonia in the Elderly
PLOS ONE | DOI:10.1371/journal.pone.0166637 November 15, 2016 11 / 11
